Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand
暂无分享,去创建一个
S. Mundlos | A. Trumpp | J. David | U. Kornak | M. Schweizer | J. Luther | M. Amling | D. Keller | T. Schinke | T. Rolvien | S. Teufel | R. Oheim | T. Koehne | T. Yorgan | S. Peters | M. Neven | E. Bockamp | Nele Vollersen | S. Rosigkeit | N. Liao | Lorenz Ulsamer
[1] C. Ambrose,et al. Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis , 2017, The Journal of clinical investigation.
[2] T. Sajobi,et al. Sex‐ and Site‐Specific Normative Data Curves for HR‐pQCT , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] O. Mäkitie,et al. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study , 2016, The Journal of clinical endocrinology and metabolism.
[4] Serge Ferrari,et al. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis , 2016, Therapeutic advances in musculoskeletal disease.
[5] B. Williams. Genetically engineered mouse models to evaluate the role of Wnt secretion in bone development and homeostasis , 2016, American journal of medical genetics. Part C, Seminars in medical genetics.
[6] S. Khosla,et al. Osteoclast TGF‐β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] M. Amling,et al. The Anti‐Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5 , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] M. Djuric,et al. Age- and Sex-Specific Bone Structure Patterns Portend Bone Fragility in Radii and Tibiae in Relation to Osteodensitometry: A High-Resolution Peripheral Quantitative Computed Tomography Study in 385 Individuals. , 2015, The journals of gerontology. Series A, Biological sciences and medical sciences.
[9] C. Ambrose,et al. The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations. , 2014, Human molecular genetics.
[10] T. Schinke,et al. Relevance of Wnt signaling for osteoanabolic therapy , 2014, Molecular and Cellular Therapies.
[11] J. David,et al. Inhibition of Bone Remodeling in Young Mice by Bisphosphonate Displaces the Plasma Cell Niche into the Spleen , 2014, The Journal of Immunology.
[12] D. Graves,et al. Non-canonical Wnt4 prevents skeletal aging and inflammation by inhibiting NF-κB , 2014, Nature Medicine.
[13] Jacques P. Brown,et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. , 2014, Canadian family physician Medecin de famille canadien.
[14] S. Ettenberg,et al. Reversing LRP5‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] A. Robling,et al. Sclerostin Inhibition Reverses Skeletal Fragility in an Lrp5-Deficient Mouse Model of OPPG Syndrome , 2013, Science Translational Medicine.
[16] Hang Lee,et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.
[17] Cassandra R Diegel,et al. Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition , 2013, PloS one.
[18] R. Gibbs,et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. , 2013, The New England journal of medicine.
[19] S. Mundlos,et al. Mutations in WNT1 cause different forms of bone fragility. , 2013, American journal of human genetics.
[20] A. Hess,et al. PPARβ/δ governs Wnt signaling and bone turnover , 2013, Nature Medicine.
[21] F. Glorieux,et al. Mutations in WNT1 are a cause of osteogenesis imperfecta , 2013, Journal of Medical Genetics.
[22] M. Amling,et al. Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin , 2013, The Journal of cell biology.
[23] Roland Baron,et al. WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.
[24] H. Xu,et al. LRP5 and LRP6 in development and disease , 2013, Trends in Endocrinology & Metabolism.
[25] J. Kanis,et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] T. Martin,et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis , 2012, Nature Medicine.
[27] P. Sambrook,et al. Antiresorptive therapies for osteoporosis: a clinical overview , 2012, Nature Reviews Endocrinology.
[28] B. Williams,et al. Lrp5 and Lrp6 play compensatory roles in mouse intestinal development , 2012, Journal of cellular biochemistry.
[29] B. Williams,et al. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. , 2011, Developmental biology.
[30] F. Mseeh,et al. Lrp5 functions in bone to regulate bone mass , 2011, Nature Medicine.
[31] T. Rachner,et al. Osteoporosis: now and the future , 2011, The Lancet.
[32] G. Sauter,et al. Control of bone formation by the serpentine receptor Frizzled-9 , 2011, The Journal of cell biology.
[33] C. Schiff,et al. Osteoclast activity modulates B-cell development in the bone marrow , 2011, Cell Research.
[34] Heather M. Macdonald,et al. Age‐related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population‐based HR‐pQCT study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] J. David,et al. The multiple faces of autoimmune-mediated bone loss , 2010, Nature Reviews Endocrinology.
[36] J. David,et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. , 2010, Cell metabolism.
[37] A. Brivanlou,et al. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex , 2010, Nature.
[38] M. Amling,et al. Bone mineralization defects and vitamin D deficiency: Histomorphometric analysis of iliac crest bone biopsies and circulating 25‐hydroxyvitamin D in 675 patients , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] J. John Mann,et al. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum , 2008, Cell.
[40] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[41] Walter Birchmeier,et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. , 2005, Developmental cell.
[42] Xizhi Guo,et al. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. , 2005, Developmental cell.
[43] M. Bouxsein,et al. Decreased BMD and Limb Deformities in Mice Carrying Mutations in Both Lrp5 and Lrp6 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[44] J. A. Robinson,et al. High Bone Mass in Mice Expressing a Mutant LRP5 Gene , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] Jennifer J Westendorf,et al. Lymphoid Enhancer Factor-1 and β-Catenin Inhibit Runx2-dependent Transcriptional Activation of the Osteocalcin Promoter* , 2003, The Journal of Biological Chemistry.
[46] Jens Bollerslev,et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. , 2003, American journal of human genetics.
[47] Robert D Cardiff,et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.
[48] Richard P Lifton,et al. High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.
[49] Ivan Lobov,et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.
[50] J. Vahle,et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety , 2002, Toxicologic pathology.
[51] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[52] M Dioszegi,et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.
[53] E. Wagner,et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 , 2000, Nature Medicine.
[54] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[55] W. Reith,et al. Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.
[56] Harold E. Varmus,et al. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.
[57] D. Graves,et al. Wnt 4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-B , 2015 .
[58] B. Clarke,et al. Bone Mineralization Defects and Vitamin D Deficiency: Histomorphometric Analysis of Iliac Crest Bone Biopsies and Circulating 25-Hydroxyvitamin D in 675 Patients , 2010 .
[59] A. McMahon,et al. Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. , 2007, Developmental cell.
[60] Mark L. Johnson,et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.
[61] P. Dineen,et al. Now and in the future. , 1970, AORN journal.